New enzyme combo aims to break down pancreatic tumors

NCT ID NCT02921022

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug called PEGPH20 to standard chemotherapy can help shrink advanced pancreatic cancer. PEGPH20 breaks down hyaluronan, a substance that builds up in pancreatic tumors and may help them grow. The trial includes 110 people with advanced pancreatic cancer that cannot be removed by surgery. Researchers are also watching for side effects, especially blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm Thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA PANCREATIC CANCER

Contacts and locations

Locations

Hartford Healthcare Cancer Institute @ Hartford Hospital

Hartford, Connecticut, 06102, United States
Lehigh Valley Health Network

Allentown, Pennsylvania, 18103, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Miami Cancer Institute

Miami, Florida, 33143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.